Cargando…

The Effects of the FDA Warning on the Use of Droperidol by U.S. Emergency Physicians

OBJECTIVES: To determine if emergency physicians’ (EP) use of droperidol has changed since the United States Food and Drag Administration (FDA) warning of December 2001 concerning QT interval prolongation, torsade de pointes, and sudden death; and to query EP opinions regarding droperidol before and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richards, John R., Weiss, Steven J., Bretz, Stephen W., Schneir, Aaron B., Rinetti, Dauna, Derlet, Robert W.
Formato:	Texto
Lenguaje:	English
Publicado:	California Chapter of the American Academy of Emergency Medicine 2003
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906954/ https://www.ncbi.nlm.nih.gov/pubmed/20852711

Ejemplares similares

Economic Evaluation of Midazolam–Droperidol Combination, Versus Droperidol or Olanzapine for the Management of Acute Agitation in the Emergency Department: A Within-Trial Analysis
por: Yap, Celene Y. L., et al.
Publicado: (2017)

Overcrowding in U.S. EDS: A Critical Condition
por: Derlet, Robert W.
Publicado: (2002)

Ondansetron-droperidol combination vs. ondansetron or droperidol monotherapy in the prevention of postoperative nausea and vomiting
por: Matsota, Paraskevi, et al.
Publicado: (2015)

Evidence-based review and appraisal of the use of droperidol in the emergency department
por: Lai, Pei-Chun, et al.
Publicado: (2018)

Reflections on the US FDA's Warning on Direct-to-Consumer Genetic Testing
por: Yim, Seon-Hee, et al.
Publicado: (2014)

Retrospective Review of the Efficacy of Droperidol Compared to Prochlorperazine for Headache Management in the Emergency Department
por: Driller, Gabrielle K, et al.
Publicado: (2023)

The Incidence of QT Prolongation and Torsades des Pointes in Patients Receiving Droperidol in an Urban Emergency Department
por: Cole, Jon B., et al.
Publicado: (2020)

Droperidol in the Management of Phantom Limb Pain: Case Report
por: Winstead, Madison C., et al.
Publicado: (2023)

The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin
por: Anand, Kanika, et al.
Publicado: (2017)

855. Impact of FDA Black Box Warning on Fluoroquinolone and Alternative Antibiotic Use in Southeastern US Hospitals
por: Yarrington, Michael, et al.
Publicado: (2018)

The pharmacokinetics of intranasal droperidol in volunteers characterised via population modelling
por: Cooper, Isabelle, et al.
Publicado: (2018)

Assessment of Diverse Solid−State Accelerated Autoxidation Methods for Droperidol
por: Iyer, Jayant, et al.
Publicado: (2022)

Comment on “The Incidence of QT Prolongation and Torsades des Pointes in Patients Receiving Droperidol in an Urban Emergency Department”
por: DiSalvo, Philip C., et al.
Publicado: (2021)

Postoperative rhabdomyolysis due to neuroleptic malignant syndrome associated with droperidol and metoclopramide
por: Orfali, Guilherme di Camillo, et al.
Publicado: (2023)

Institutional response to FDA warning on aprotinin and impact on outcomes
por: Swaminathan, M, et al.
Publicado: (2009)

In-Flight Emergencies at 35,000 Feet
por: Derlet, Robert W., et al.
Publicado: (2005)

Ten Solutions for Emergency Department Crowding
por: Derlet, Robert W., et al.
Publicado: (2008)

Acute dystonia by droperidol during intravenous patient-controlled analgesia in young patients.
por: Park, Chang Kil, et al.
Publicado: (2002)

High dose droperidol and QT prolongation: analysis of continuous 12-lead recordings
por: Calver, Leonie, et al.
Publicado: (2014)

Respone to: “Limitations of Retrospective Chart Reviews to Determine Rare Events, and the Unknown Relative Risk of Droperidol”
por: Cole, Jon B., et al.
Publicado: (2021)

Are Some of the Cigar Warnings Mandated in the U.S. More Believable Than Others?
por: Jarman, Kristen L., et al.
Publicado: (2017)

Emergency Department Hallway Care From the Millennium to the Pandemic: A Clear and Present Danger
por: Richards, John R., et al.
Publicado: (2022)

Referral paths in the U.S. physician network
por: An, Chuankai, et al.
Publicado: (2018)

A systematic review of the effectiveness and safety of droperidol for pediatric agitation in acute care settings
por: Ramsden, Shannon C., et al.
Publicado: (2022)

U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations
por: Zuabi, Nadia, et al.
Publicado: (2016)

Point of no return: COVID-19 and the U.S. healthcare system: An emergency physician’s perspective
por: Dorsett, Maia
Publicado: (2020)

An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation
por: Chaloupka, Frank J, et al.
Publicado: (2015)

Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies
por: Hagan, John B., et al.
Publicado: (2021)

Public Perceptions of Breast Implant Complications and the FDA Boxed Warning on Implants
por: Hyland, Colby J., et al.
Publicado: (2022)

USE OF FDA-APPROVED ALZHEIMER’S DISEASE MEDICATIONS AMONG NON-INSTITUTIONALIZED U.S. ADULTS AGE 60 YEARS AND OLDER
por: Frenk, Steven, et al.
Publicado: (2019)

Parental satisfaction of U.S. physicians: associated factors and comparison with the general U.S. working population
por: Shanafelt, Tait D., et al.
Publicado: (2016)

Emerging Infections in 2001
por: Derlet, Robert W.
Publicado: (2001)

Trends in clinical trial investigator workforce and turnover: An analysis of the U.S. FDA 1572 BMIS database
por: Fordyce, Christopher B., et al.
Publicado: (2019)

Older U.S. Adults With Nocturia Often Cannot Use the Only FDA-Approved Drugs for the Condition
por: Johnson, Theodore, et al.
Publicado: (2020)

Treating Influenza in the Emergency Department
por: Derlet, Robert. W.
Publicado: (2001)

Droperidol vs ondansetrón en la prevención del vómito postoperatorio en colecistectomía laparoscópica
por: Estévez Hernández, Oralia
Publicado: (2000)

Comparing Physician Assistant and Nurse Practitioner Practice in U.S. Emergency Departments, 2010–2017
por: Wu, Fred, et al.
Publicado: (2021)

Overcrowding in Emergency Departments: Effects on Patients
por: Derlet, Robert W.
Publicado: (2000)

Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs
por: Ahuja, Vishal, et al.
Publicado: (2015)

1863. Antibiotic Prescribing Before and After an FDA Boxed Warning on Fluoroquinolones in 2016
por: Willis, Zachary, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2q9eup1u0nq0vitenjgsrjn7lu